1.Exhaled Volatile Organic Compounds Analysis in Patients with Pulmonary Complications after Abdominal Surgery
Bin WANG ; Xiaoli ZHANG ; Xiaochun YANG ; Jingyu WANG ; Youzhong AN ; Yi FENG
Journal of Sun Yat-sen University(Medical Sciences) 2025;46(3):528-534
ObjectiveTo identify the characteristic exhaled volatile organic compounds (VOCs) associated with postoperative pulmonary complications (PPCs) in patients after abdominal surgery. MethodsThis study prospectively enrolled 76 patients with tracheal intubation who were transferred to intensive care unit (ICU) after abdominal surgery at Peking University People's Hospital between December 10, 2022 and June 30, 2023. The patients' basic information was collected during their perioperative period, and their exhaled VOCs were collected within 24 hours after their admission to the ICU, and then analyzed by gas chromatography and mass spectrometry (GC-MS). According to whether PPCs occurred 24 hours after surgery, the patients were divided into PPCs group (n=44) and non-PPCs group (n=32), and the differences of VOCs were compared between the two groups. Lasso regression analysis was used to screen the valuable variables of VOCs, and Logistics regression analysis to determine the characteristic VOCs associated with the occurrence of PPCs. ResultsAmong the 76 patients, 44 had PPCs and 32 had no PPCs. Lasso regression analysis screened 4 PPCs-related compounds from exhaled VOCs of two groups for further analysis and Logistics regression analysis showed that the increase of 1-Hexadecanol content in exhaled breath was significantly correlated with the occurrence of PPCs (OR: 1.000, P=0.002). ConclusionThis study indicated that the increased content of 1-Hexadecanol in patients' exhaled breath after abdominal surgery may be associated with the occurrence of PPCs.
2.Assessment of perioperative pulmonary fluid volume using remote dielectric sensing (ReDSTM) non-invasive lung fluid measurement technology in transcatheter tricuspid valve-in-valve implantation: The first case report
Yuliang LONG ; Yuan ZHANG ; Xiaochun ZHANG ; Peng WANG ; Xiaotong CUI ; Wenzhi PAN ; Daxin ZHOU ; Junbo GE
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery 2025;32(04):571-574
One of its primary surgical treatments of tricuspid regurgitation is tricuspid valve biological valve replacement. Catheter tricuspid valve-in-valve implantation is a novel interventional alternative for biological valve failure. The non-invasive lung fluid measuring device remote dielectric sensing (ReDSTM) has been increasingly incorporated into clinical practice as a means of monitoring chronic heart failure in recent years. This report describes the process and outcomes of the first instance of perioperative lung fluid volume evaluation following transcatheter tricuspid valve implantation utilizing ReDSTM technology. The patient has a short-term, substantial increase in postoperative lung fluid volume as compared to baseline.
3.The Effectiveness and Safety of Aromatase Inhibitors Combined with r-hGH in Improving Final Adult Height in Late-Pubertal Boys: A Retrospective Cohort Study
Jinshui HE ; Wei TANG ; Shuyun ZHANG ; Xiaochun SHEN ; Yibin ZHAO
Medical Journal of Peking Union Medical College Hospital 2025;17(2):445-451
To investigate the efficacy and safety of aromatase inhibitors (AI) combined with recombinant human growth hormone (r-hGH) in improving the final height (FH) of boys in late puberty. Clinical data of pubertal boys with growth deceleration, consecutively admitted to the Department of Child Growth and Development, Zhangzhou Affiliated Hospital of Fujian Medical University between February 2017 and December 2022, were collected. According to different treatment regimens, the patients were divided into the GH group, the AI+GH group, and the control group. The GH group received r-hGH monotherapy[dose 0.18-0.2 U/(kg·d)] until the growth velocity was less than 0.5 cm/3 months. The AI+GH group received anastrozole 1 mg/d or letrozole 2.5 mg/d combined with r-hGH[dose 0.18-0.2 U/(kg·d)]; AI was discontinued after 1 year, while r-hGH was continued until the growth velocity was less than 0.5 cm/3 months. The control group did not receive any height-promoting drugs. All patients were followed up outpatient every 3 months until FH was reached, monitoring growth development indicators and adverse reactions. The efficacy and safety were compared between the GH group and the AI+GH group. A total of 69 pubertal boys meeting the inclusion and exclusion criteria were enrolled, including 28 in the GH group, 17 in the AI+GH group, and 24 in the control group. There were no statistically significant differences among the three groups in terms of height, bone age, height standard deviation score for bone age (HtSDSBA), target height (TH), and predicted adult height for bone age (PAHBA) (all Combination therapy with AI and r-hGH can effectively improve the FH of boys in late puberty, but adverse reactions require close monitoring during treatment.
4.Role of G protein-coupled receptor 120 in respiratory diseases
Yanyan ZHAO ; Lijun ZHANG ; Xiaochun ZHANG ; Xiangyan LIANG ; Yufeng ZHAO
Basic & Clinical Medicine 2025;45(2):244-248
G protein-coupled receptor 120(GPR120)is one of the membrane receptors for long chain free fatty acids and is distributed in alveolus macrophages and airway epithelial Club cells.GPR120 activation alleviates the inflammation of respiratory tract,improves airway hyper-responsiveness,stimulates proliferation of Club cells and promotes the repair of respiratory epithelium,which may attenuate asthma and acute lung injury.
5.Plasma homocysteine concentration and MTHFR C677T polymorphism are related to ischemic stroke
Yuchao ZHANG ; Mingzhang XIE ; Mengmeng ZHAO ; Xiaochun ZHOU ; Chenyan YANG ; Yanxuan LIU
Basic & Clinical Medicine 2025;45(3):331-335
Objective To investigate the correlation of plasma homocysteine(Hcy)level and the polymorphisms of its key metabolic enzymes methylenetetrahy-drofolate reductase(MTHFR)gene with ischemic stroke(IS).Methods A total of 310 patients with IS were enrolled as the case group and 330 healthy subjects during the same period were selected as the control group.Plasma Hcy concentration was detected by enzyme cycling method,and the real-time fluorescent quantitative PCR(RT-qPCR)was used to detecte the genotypes of MTHFR C677T.Results The frequencies of TT genotype(36.13%),CT genotype(10.00%)and T allele(28.06%)of MTHFR gene C677T locus in stroke patients were significantly higher than that in control group(P<0.05).The frequency of the TT genotype was significantly higher in IS group compared to control group,indicating a recessive mode of inheritance(P<0.05);In the dominant mode of inheritance,the frequency of CT+TT genotype in IS group was also significantly higher than that in control group(P<0.05);The plasma Hay concentration of MTHFR C677T genotype TT,CT and CC patients was statistically different(P<0.05),which were(20.91±6.78)μmol/L(17.20±5.39)μmol/L,(14.35±4.32)μmol/L,respectively;The area under the ROC curve(AUC)of plas-ma total Hcy level was 0.610(95%CI:0.566~0.653,P<0.001).It indicated that it might play an impor-tant role in predicting the risk of suffering from IS.Multivariate Logistic regression analysis showed that plasma Hcy level and MTHFR C677T gene polymorphism were important risk factors of IS.Conclusions Elevated plasma Hcy level is associated with IS,and the synergistic effect of elevated Hcy level and MTHFR C677T gene mutation may increase the risk of IS.
6.Association of MTHFR C677T gene polymorphism with serum Hcy level and subtypes of ischemic stroke
Yuchao ZHANG ; Mingzhang XIE ; Xiaochun ZHOU ; Mengmeng ZHAO ; Chenyan YANG ; Yanxuan LIU
Basic & Clinical Medicine 2025;45(12):1614-1618
Objective To investigate the relationship between methylenetetra-hydrofolatereductase(MTHFR)gene polymorphism and serum homocysteine(Hcy)level and subtypes of ischemic stroke(IS).Methods The study was conducted according to the matched principle of case-control design,310 patients with IS and 330 healthy people during the same period were selected as the case group and the control group.Recycling enzyme method and the real-time fluorescent quantitative PCR(RT-qPCR)method were used to detect the level of serum Hcy and the genotypes of MTHFR C677T,respectively.Results There was a significantly difference in MTHFR C677T genotype and allele frequency between the case and control groups(P<0.05).The correlation analysis with different subtypes indicated that the frequencies of CT genotype(38.02%),TT genotype(10.74%),and T allele(29.75%)were significantly different in the LAA group(OR=1.662,95%CI:1.058-2.608,P<0.05;OR=2.373,95%CI:1.110-5.073,P<0.05;OR=1.663,95%CI:1.190-2.323,P<0.05);The frequencies of TT genotype(10.53%)and T allele(27.30%)in SAO group were also significantly different(OR=2.130,95%CI:1.046-4.336,P<0.05;OR=1.474,95%CI:1.075-2.021,P<0.05).Further analysis of serum Hcy level showed that LAA group(19.55±5.61)μmol/L and SAO group(16.37±5.20)μmol/L were significantly higher than the control group(14.46±4.61)μmol/L(P<0.001);Among the patients of both subtypes the serum Hcy levels in those with CT genotypes and TT genotypes were significantly higher than those in patients of CC genotypes(P<0.001).Conclusions The gene polymorphism of MTHFR C677T has a significant effect on Hcy level in pa-tients with LAA and SAO stroke.
7.Systemic comparison of molecular characteristics in different skin fibroblast senescent models.
Xiaokai FANG ; Shan ZHANG ; Mingyang WU ; Yang LUO ; Xingyu CHEN ; Yuan ZHOU ; Yu ZHANG ; Xiaochun LIU ; Xu YAO
Chinese Medical Journal 2025;138(17):2180-2191
BACKGROUND:
Senescent human skin primary fibroblast (FB) models have been established for studying aging-related, proliferative, and inflammatory skin diseases. The aim of this study was to compare the transcriptome characteristics of human primary dermal FBs from children and the elderly with four senescence models.
METHODS:
Human skin primary FBs were obtained from healthy children (FB-C) and elderly donors (FB-E). Senescence models were generated by ultraviolet B irradiation (FB-UVB), D-galactose stimulation (FB-D-gal), atazanavir treatment (FB-ATV), and replication exhaustion induction (FB-P30). Flow cytometry, immunofluorescence staining, real-time quantitative polymerase chain reaction, co-culturing with immune cells, and bulk RNA sequencing were used for systematic comparisons of the models.
RESULTS:
In comparison with FB-C, FB-E showed elevated expression of senescence-related genes related to the skin barrier and extracellular matrix, proinflammatory factors, chemokines, oxidative stress, and complement factors. In comparison with FB-E, FB-UVB and FB-ATV showed higher levels of senescence and expression of the genes related to the senescence-associated secretory phenotype (SASP), and their shaped immune microenvironment highly facilitated the activation of downstream immune cells, including T cells, macrophages, and natural killer cells. FB-P30 was most similar to FB-E in terms of general transcriptome features, such as FB migration and proliferation, and aging-related characteristics. FB-D-gal showed the lowest expression levels of senescence-related genes. In comparisons with the single-cell RNA sequencing results, FB-E showed almost complete simulation of the transcriptional spectrum of FBs in elderly patients with atopic dermatitis, followed by FB-P30 and FB-UVB. FB-E and FB-P30 showed higher similarity with the FBs in keloids.
CONCLUSIONS
Each senescent FB model exhibited different characteristics. In addition to showing upregulated expression of natural senescence features, FB-UVB and FB-ATV showed high expression levels of senescence-related genes, including those involved in the SASP, and FB-P30 showed the greatest similarity with FB-E. However, D-galactose-stimulated FBs did not clearly present aging characteristics.
Humans
;
Fibroblasts/drug effects*
;
Cellular Senescence/physiology*
;
Skin/metabolism*
;
Child
;
Transcriptome/genetics*
;
Aged
;
Ultraviolet Rays
;
Cells, Cultured
;
Galactose/pharmacology*
8.Dynamic gait parameters reveal long-term compensatory characteristics in knee joint function recovery following anterior cruciate ligament reconstruction: A retrospective cohort study.
Qitai LIN ; Zehao LI ; Meiming LI ; Yongsheng MA ; Wenming YANG ; Yugang XING ; Yang LIU ; Ruifeng LIANG ; Yixuan ZHANG ; Ruipeng ZHAO ; Wangping DUAN ; Pengcui LI ; Xiaochun WEI
Chinese Medical Journal 2025;138(22):3016-3018
9.Adaptive immunity in the neuroinflammation of Alzheimer's disease.
Hanchen LIU ; Yun CHEN ; Jing ZHANG ; Xiaochun CHEN
Chinese Medical Journal 2025;138(17):2116-2129
Alzheimer's disease (AD) is the most common cause of dementia and is a growing public health challenge. Neuroinflammation has been proposed as a prominent pathological feature of AD and has traditionally been attributed to the innate immune system. However, emerging evidence highlights the involvement of adaptive immunity, particularly T and B lymphocytes, in the neuroinflammatory processes of AD. It remains unclear how adaptive immune responses, originally intended to protect the body, contribute to chronic inflammation and neuronal dysfunction in AD. Here, we review the roles of adaptive immunity, cellular composition, and niches and their contribution to AD development and progression. Notably, we synthesize the crosstalk between adaptive immunity and the innate immune system of the central nervous system (CNS), which is mainly mediated by glial cells and myeloid cells, and their interrelationships with amyloid-β (Aβ)/Tau pathology. We hypothesized that the alterations observed in innate immunity in AD mirror age-related immune alterations, whereas the dysregulation of adaptive immunity contributes more accurately to disease-specific immune responses. Targeting adaptive immunity in the context of neuroinflammation may provide new insights into potential therapeutic strategies designed to modulate immune responses, thereby facilitating the diagnosis, intervention, and treatment of AD.
Alzheimer Disease/metabolism*
;
Humans
;
Adaptive Immunity/physiology*
;
Immunity, Innate/immunology*
;
Animals
;
Neuroinflammatory Diseases/immunology*
;
Inflammation/immunology*
;
Amyloid beta-Peptides/metabolism*
10.Recommendations for the clinical use of anti-amyloid-β monoclonal antibody for Alzheimer's disease(2025)
Nan ZHI ; Jinwen XIAO ; Rujing REN ; Binyin LI ; Jintao WANG ; Jieli GENG ; Wenwei CAO ; Yaying SONG ; Hualong WANG ; Shuguang CHU ; Guoping PENG ; Jun LIU ; Xiaoyun LIU ; Fang YUAN ; Wen WANG ; Ronghua DOU ; Xia LI ; Ling YUE ; Wenshi WEI ; Xiaoling PAN ; Xiangyang ZHU ; Dian HE ; Weinü FAN ; Jingping SHI ; Nan ZHANG ; Hui ZHAO ; Qin CHEN ; Cuibai WEI ; Xiaochun CHEN ; Gang WANG
Journal of Chongqing Medical University 2025;50(9):1133-1140
In recent years,significant breakthroughs have been achieved in the immunotherapy for Alzheimer's disease.In line with global advancements,two anti-amyloid-β monoclonal antibodies have been approved and successfully launched in China for clinical use.Lecanemab and Donanemab were officially used in June 2024 and April 2025 in China,respectively.In order to standardize the rational and safe application of anti-amyloid-β monoclonal antibodies for Alzheimer's disease in China,this article integrates recom-mendations from the clinical trials and real-world experience from the author's team and domestic peers to further update the recom-mendations for the clinical use of anti-amyloid-β monoclonal antibody based on the 2024 version.It includes indications for therapy,pre-treatment evaluation and preparation,administration protocols and safety measures during treatment,and post-treatment monitor-ing strategies.

Result Analysis
Print
Save
E-mail